{"id":2160,"date":"2026-07-21T15:55:42","date_gmt":"2026-07-21T13:55:42","guid":{"rendered":"https:\/\/filiere-ia.fr\/2024-sector-day\/jdlfia-2024-table-1\/"},"modified":"2026-07-22T16:05:32","modified_gmt":"2026-07-22T14:05:32","slug":"jdlfia-2024-table-1","status":"publish","type":"page","link":"https:\/\/filiere-ia.fr\/en\/2024-sector-day\/jdlfia-2024-table-1\/","title":{"rendered":"JDLFIA 2024 – Table 1"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
JFIAC 2024: Round Table 1<\/div>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Round Table 1: <\/b>Can real-world data support early access?<\/h1>\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tDiscover the speakers' profiles<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

How can the reuse of health data generated in routine practice provide higher quality patient follow-up data, including after early access has ended? How can early access data help us demonstrate the adoption of innovation as well as equity of access?<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Speakers<\/h2>\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tMarianne Duperray<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tDirector of Recommendations and Medicines at the National Cancer Institute<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tAt the Institute since 2007 and currently in charge of the Recommendations and Medicines Department, which produces clinical practice guidelines on cancer management strategies, reference frameworks and tools for general practitioners, expertise in the field of shortages and the prevention and management of adverse effects of anticancer drugs, as well as all content for patients and their families as part of the Cancer Info collection. A horizon scanning initiative has also been developed within the department since 2019. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tNathalie Varoqueaux<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tExecutive Medical Director at Amgen France<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Nathalie Varoqueaux MD PhD is the Medical Director of Amgen France.<\/p>

A specialist in hematology, she holds a PhD in Science from Paris VI Pierre and Marie Curie University in cellular and molecular biology.<\/p>

She has held various senior positions in several pharmaceutical companies, such as Roche, Alexion, and AstraZeneca, in medical affairs, business development, and pharmacovigilance.<\/p>

N. Varoqueaux is also Vice-President of ARIIS, Vice-President of the Research and Innovation Commission of LEEM, and a board member of FIAC.<\/p>

<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tNicolas Ozan<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tMedical Director of Oncology and Hematology at AstraZeneca France<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

After practicing clinically, Nicolas joined the pharmaceutical industry in various medical roles across different companies, covering immuno-oncology, cell therapy, and targeted therapies, among others.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tCamille Thomassin<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tHead of the Real-World Data Coordination Unit at the DEAI department of the HAS<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tCamille Thomassin, Doctor of Pharmacy, has been the Head of the Real-World Data Coordination Unit at the FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS) since October 2022. The mission of this unit is, among others, to: coordinate the implementation and monitoring of post-listing studies for reimbursement, as well as the collection of data within the framework of early access for medicines. Previously, until 2017, Camille Thomassin was a benefit\/risk assessor at the NATIONAL AGENCY FOR THE SAFETY OF MEDICINES AND HEALTH PRODUCTS. Then, from 2017 to 2022, she reviewed dossiers for the Transparency Commission regarding the reimbursement of medicines and coordinated the production of scientific opinions and international activities at the HAS, in anticipation of the implementation of the European regulation on health technology assessment.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tPierre Demolis<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tVice Chair of SAWP at the European Medicines Agency<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tLaure Gu\u00e9roult Accolas<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tFounder and Director of Patients en R\u00e9seau<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tPhilippe Bonnard<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tMedical Director of Oncology at MSD France<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

JFIAC 2024: Round Table 1 Round Table 1: Can real-world data support early access? Discover the speakers’ profiles How can the reuse of health data generated in routine practice provide higher quality patient follow-up data, including after early access has ended? How can early access data help us demonstrate the adoption of innovation as well […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":2154,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-2160","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/pages\/2160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/comments?post=2160"}],"version-history":[{"count":2,"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/pages\/2160\/revisions"}],"predecessor-version":[{"id":2300,"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/pages\/2160\/revisions\/2300"}],"up":[{"embeddable":true,"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/pages\/2154"}],"wp:attachment":[{"href":"https:\/\/filiere-ia.fr\/en\/wp-json\/wp\/v2\/media?parent=2160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}